Tenasors Medical is developing a new generation of smart medical devices for gastrointestinal (GI) endoscopy — designed to make procedures safer, diagnosis more accurate and treatment more precise.
Its lead product, the WTI (Wall Thickness Indicator), is an advanced probe that combines optical fiber technology, AI-driven analytics and a real-time automated safety stop. It measures the thickness of tissue layers at the micron level within milliseconds, giving physicians precise feedback before they take a biopsy or perform a treatment.
This matters most for patients with inflammatory bowel diseases such as Crohn's disease and ulcerative colitis. Today, diagnosis relies on physical biopsies and a 5-to-7-day wait for pathology results. These patients' intestinal walls are often inflamed, thin and fragile, which puts them at higher risk of injury during procedures.
Tenasors aims to change that: an “optical biopsy” that profiles intestinal layers and inflammation severity on the spot, the ability to deliver medication directly to the affected site during the same procedure (“see and treat”), and added protection against tissue injury. The company estimates its technology can shorten procedures by up to 30% and increase daily procedural capacity by 20–30%.
Looking ahead, Tenasors is building a platform that can expand to other organs, including the small intestine, stomach and liver, and grow from a diagnostic tool into a full therapeutic and AI-powered decision-support system.
DKF has backed Tenasors from its inception, with DKF founder Alin Kipnis as a cornerstone investor and partner. It is a clear example of the Health-Tech investments we believe in: technology that puts patient safety first and turns medical innovation into better care.